{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:16:02Z","timestamp":1785406562637,"version":"3.56.0"},"posted":{"date-parts":[[2026,3,31]]},"group-title":"Neuroscience","reference-count":47,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["R01EY032478"],"award-info":[{"award-number":["R01EY032478"]}],"id":[{"id":"https:\/\/ror.org\/03wkg3b53","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Open-angle glaucoma (OAG) affects approximately 57.5 million individuals worldwide and is characterized by the progressive loss of retinal ganglion cells (RGC) and irreversible optic nerve damage resulting from chronic ocular hypertension. Intraocular pressure (IOP) is the only major modifiable risk factor in OAG and clinical treatments necessarily aim to lower IOP in order to preserve RGCs and prevent vison loss. Pharmacological therapies, such as prostaglandin analog containing eye drops, are known to be effective at reducing IOP, but are critically undermined by poor patient compliance and are unable to control for potentially damaging diurnal fluctuations in IOP, leading to vision loss even in patient\u2019s diagnosed early. Herein we evaluate the effectiveness of a long-acting, single use, prostaglandin-based recombinant adeno-associated virus (rAAV)-mediated IOP-lowering gene therapy treatment in glaucomatous DBA\/2J mice and demonstrate that sustained IOP reduction leads to preservation of both optic nerve anatomy and function in end-stage glaucomatous disease.<\/jats:p>\n                <jats:sec>\n                  <jats:title>One Sentence Summary<\/jats:title>\n                  <jats:p>IOP-lowering gene therapy provides partial anatomical and functional rescue in glaucomatous mouse model following single dose treatment<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.03.27.714838","type":"posted-content","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:25:37Z","timestamp":1774967137000},"source":"Crossref","is-referenced-by-count":0,"title":["rAAV prostaglandin-based gene therapy lowers intraocular pressure and preserves optic nerve health in glaucomatous DBA\/2J mice"],"prefix":"10.64898","author":[{"given":"Kristina J.","family":"Chern","sequence":"first","affiliation":[{"name":"Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Fehrman","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin J.","family":"Marcoe","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Lipinski","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, WI, USA"},{"name":"Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026040308550547000_2026.03.27.714838v1.1","first-page":"e11686","article-title":"Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future","volume":"12","year":"2020","journal-title":"Cureus"},{"key":"2026040308550547000_2026.03.27.714838v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2012.07.001"},{"key":"2026040308550547000_2026.03.27.714838v1.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"},{"key":"2026040308550547000_2026.03.27.714838v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2016.07.013"},{"key":"2026040308550547000_2026.03.27.714838v1.5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ICU.0000000000000551","article-title":"Influence of new treatment modalities on adherence in glaucoma","volume":"30","year":"2019","journal-title":"Current opinion in ophthalmology"},{"key":"2026040308550547000_2026.03.27.714838v1.6","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0b013e3182058ead"},{"key":"2026040308550547000_2026.03.27.714838v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701674"},{"key":"2026040308550547000_2026.03.27.714838v1.8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0333-6"},{"key":"2026040308550547000_2026.03.27.714838v1.9","first-page":"903","article-title":"Managing adverse effects of glaucoma medications","volume":"8","year":"2014","journal-title":"Clinical ophthalmology"},{"key":"2026040308550547000_2026.03.27.714838v1.10","doi-asserted-by":"publisher","DOI":"10.1097\/01.icu.0000156139.05323.26"},{"key":"2026040308550547000_2026.03.27.714838v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.09.004"},{"key":"2026040308550547000_2026.03.27.714838v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.01.047"},{"key":"2026040308550547000_2026.03.27.714838v1.13","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200004000-00002"},{"key":"2026040308550547000_2026.03.27.714838v1.14","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1038\/s41598-017-09379-8","article-title":"Long Term Glaucoma Drug Delivery Using a Topically Retained Gel\/Microsphere Eye Drop","volume":"7","year":"2017","journal-title":"Scientific reports"},{"key":"2026040308550547000_2026.03.27.714838v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.018"},{"key":"2026040308550547000_2026.03.27.714838v1.16","first-page":"98","article-title":"New concepts for glaucoma implants--controlled aqueous humor drainage, encapsulation prevention and local drug delivery","volume":"14","year":"2013","journal-title":"Curr Pharm Biotechnol"},{"key":"2026040308550547000_2026.03.27.714838v1.17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/jop.2018.0067","article-title":"Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues","volume":"35","year":"2019","journal-title":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"key":"2026040308550547000_2026.03.27.714838v1.18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40266-020-00769-8","article-title":"Bimatoprost Implant: First Approval","volume":"37","year":"2020","journal-title":"Drugs Aging"},{"key":"2026040308550547000_2026.03.27.714838v1.19","first-page":"116","article-title":"Durysta - a bimatoprost implant for glaucoma","volume":"62","year":"2020","journal-title":"Med Lett Drugs Ther"},{"key":"2026040308550547000_2026.03.27.714838v1.20","doi-asserted-by":"crossref","unstructured":"Castro, BFM , Steel, JC , and Layton, CJ (2023). AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies. BioDrugs.","DOI":"10.1007\/s40259-023-00629-y"},{"key":"2026040308550547000_2026.03.27.714838v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.278"},{"key":"2026040308550547000_2026.03.27.714838v1.22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/02713683.2014.884593","article-title":"Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo","volume":"39","year":"2014","journal-title":"Current eye research"},{"key":"2026040308550547000_2026.03.27.714838v1.23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s42003-022-04134-w","article-title":"Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats","volume":"5","year":"2022","journal-title":"Commun Biol"},{"key":"2026040308550547000_2026.03.27.714838v1.24","first-page":"951","article-title":"Essential iris atrophy, pigment dispersion, and glaucoma in DBA\/2J mice","volume":"39","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026040308550547000_2026.03.27.714838v1.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407357102"},{"key":"2026040308550547000_2026.03.27.714838v1.26","doi-asserted-by":"publisher","DOI":"10.1017\/S0952523805225130"},{"key":"2026040308550547000_2026.03.27.714838v1.27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-7-66"},{"key":"2026040308550547000_2026.03.27.714838v1.28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000444057","article-title":"Effect of Antiglaucoma Medicine on Intraocular Pressure in DBA\/2J Mice","volume":"55","year":"2016","journal-title":"Ophthalmic research"},{"key":"2026040308550547000_2026.03.27.714838v1.29","first-page":"232","article-title":"Aqueous Humour dynamics of DBA\/2J mice and the intraocular pressure response to latanoprost and pilocarpine","volume":"19","year":"2019","journal-title":"Chin J Ophthalmol and Otorhinolaryngol"},{"key":"2026040308550547000_2026.03.27.714838v1.30","first-page":"588","article-title":"Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes","volume":"22","year":"1982","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026040308550547000_2026.03.27.714838v1.31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF02173538","article-title":"The effects of prostaglandin F2 alpha in the human eye","volume":"222","year":"1985","journal-title":"Graefe\u2019s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"key":"2026040308550547000_2026.03.27.714838v1.32","first-page":"1126","article-title":"A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond: the Proctor Lecture","volume":"42","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026040308550547000_2026.03.27.714838v1.33","first-page":"1134","article-title":"From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture","volume":"42","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026040308550547000_2026.03.27.714838v1.34","doi-asserted-by":"crossref","unstructured":"Zaharia, AC , Dumitrescu, OM , Radu, M , and Rogoz, RE (2022). Adherence to Therapy in Glaucoma Treatment-A Review. J Pers Med 12.","DOI":"10.3390\/jpm12040514"},{"key":"2026040308550547000_2026.03.27.714838v1.35","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40123-022-00527-6","article-title":"Single Administration of Intracameral Bimatoprost Implant 10 microg in Patients with Open-Angle Glaucoma or Ocular Hypertension","volume":"11","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"2026040308550547000_2026.03.27.714838v1.36","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1130_17"},{"key":"2026040308550547000_2026.03.27.714838v1.37","first-page":"292","article-title":"Primary open angle glaucoma: inherited primary open angle glaucoma in the beagle","volume":"102","year":"1981","journal-title":"Am J Pathol"},{"key":"2026040308550547000_2026.03.27.714838v1.38","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10796"},{"key":"2026040308550547000_2026.03.27.714838v1.39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/vop.12908","article-title":"Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG)","volume":"24","year":"2021","journal-title":"Vet Ophthalmol"},{"key":"2026040308550547000_2026.03.27.714838v1.40","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/ceo.12992","article-title":"DBA\/2J mouse model for experimental glaucoma: pitfalls and problems","volume":"45","year":"2017","journal-title":"Clinical & experimental ophthalmology"},{"key":"2026040308550547000_2026.03.27.714838v1.41","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.68"},{"key":"2026040308550547000_2026.03.27.714838v1.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119416110"},{"key":"2026040308550547000_2026.03.27.714838v1.43","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0733"},{"key":"2026040308550547000_2026.03.27.714838v1.44","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0483"},{"key":"2026040308550547000_2026.03.27.714838v1.45","doi-asserted-by":"crossref","first-page":"16839","DOI":"10.1038\/s41598-021-96107-y","article-title":"Effects of intravitreal injection of siRNA against caspase-2 on retinal and optic nerve degeneration in air blast induced ocular trauma","volume":"11","year":"2021","journal-title":"Scientific reports"},{"key":"2026040308550547000_2026.03.27.714838v1.46","doi-asserted-by":"crossref","unstructured":"Wu, HJ , Hazlewood, RJ , Kuchtey, J , and Kuchtey, RW (2018). Enlarged Optic Nerve Axons and Reduced Visual Function in Mice with Defective Microfibrils. eNeuro 5.","DOI":"10.1523\/ENEURO.0260-18.2018"},{"key":"2026040308550547000_2026.03.27.714838v1.47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-7522-8_2","article-title":"Small and Micro-Scale Recombinant Adeno-Associated Virus Production and Purification for Ocular Gene Therapy Applications","volume":"1715","year":"2018","journal-title":"Methods Mol Biol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.03.27.714838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:55:15Z","timestamp":1775231715000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.03.27.714838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":47,"URL":"https:\/\/doi.org\/10.64898\/2026.03.27.714838","relation":{},"subject":[],"published":{"date-parts":[[2026,3,31]]},"subtype":"preprint"}}